EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Genetic mutations and inhibitors of p300 and CBP

Agnieszka Robaszkiewicz, Philip A Cole

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189599

DOI: 10.1016/j.bbcan.2026.189599 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Agnieszka Robaszkiewicz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland. Electronic address: agnieszka.ro…. Hauptthemen laut MEDLINE: CREB-Binding Protein, Mutation, E1A-Associated p300 Protein, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Blood Cancer United.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The p300 and CBP highly homologous acetyltransferases, are linked to malignant transformation and cancer progression. The longstanding attempts to find small molecules to block these enzymes in cancer have led to the identification of two inhibitor classes that target the acetyltransferase catalytic domain (HAT) or acetylated protein recognizing bromodomain (BRD), and related pharmacological agents such as dual BRD/BET inhibitors and PROTAC degraders. Although p300 and CBP behave as a synthetic lethal pair and their inhibition emerged promising in anticancer in vitro and in vivo studies, clinical approval has lagged. In this review we examine mutations in EP300 and CREBBP and describe their frequency and potential impacts. Particular attention is paid to genetic alterations in HAT and bromodomain simultaneously in EP300 and CREBBP, and we discuss how these mutations may influence efficacy of pharmacological agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CREB-Binding ProteinMutationE1A-Associated p300 ProteinNeoplasmsp300-CBP Transcription FactorsAntineoplastic AgentsEnzyme InhibitorsHumansAnimalsProteolysis Targeting Chimera

Stichwörter der Autor:innen

AcetyltransferaseCREB-binding protein (CBP)DNA mutation typesE1A-associated protein (p300)HAT/BRD inhibitorsPROTAC degraderscancer treatment

Substanzen

CREB-Binding ProteinCREBBP protein, humanE1A-Associated p300 ProteinEP300 protein, humanp300-CBP Transcription FactorsProteolysis Targeting ChimeraAntineoplastic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland. Electronic address: agnieszka.robaszkiewicz@biol.uni.lodz.pl.
  • Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United…

Förderung

  • Blood Cancer United

Zitieren

APA

Robaszkiewicz, A., & Cole, P. A. (2026). Genetic mutations and inhibitors of p300 and CBP. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189599. https://doi.org/10.1016/j.bbcan.2026.189599

Vancouver

Robaszkiewicz A, Cole PA. Genetic mutations and inhibitors of p300 and CBP. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189599. doi:10.1016/j.bbcan.2026.189599

BibTeX
@article{Robaszkiewicz2026,
  author = {Robaszkiewicz, Agnieszka and Cole, Philip A},
  title = {Genetic mutations and inhibitors of p300 and CBP},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  volume = {1881},
  number = {4},
  pages = {189599},
  doi = {10.1016/j.bbcan.2026.189599}
}
Kostenlos starten →